Sofinnova Management VIII, L.L.C. 13F Holdings · last filed Q4 2017
Sofinnova Management VIII, L.L.C. reported 8 securities worth $183.19M in its SEC 13F filing for Q4 2017 (period ended 2017-12-31). Top holdings: NCNA (25.76%), OBSVF (25.31%), ACRS (20.72%). Among its top 25 positions this quarter: 2 added.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | NCNA | NuCana plc | $47.2M | 25.76% | 4.7M | Added |
| 2 | OBSVF | ObsEva SA | $46.4M | 25.31% | 4.7M | Added |
| 3 | ACRS | Aclaris Therapeutics, Inc. | $38.0M | 20.72% | 1.5M | Hold |
| 4 | ONCE | Spark Therapeutics, Inc. | $24.7M | 13.51% | 481,270 | Hold |
| 5 | NTRA | Natera, Inc. | $13.9M | 7.61% | 1.6M | Hold |
| 6 | EARS | Auris Medical Holding AG | $4.6M | 2.52% | 7.8M | Hold |
| 7 | OCGN | Histogenics Corporation | $4.3M | 2.32% | 2.1M | Hold |
| 8 | SYBX | Synlogic, Inc. | $4.1M | 2.25% | 424,972 | Hold |
Source: SEC Form 13F filings · as of 2017-12-31
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR